Novel treatment showing promise in patients with pleural mesothelioma

20 Apr 2018 by under Research/Treatment

Diagram showing a build up of fluid in the lining of the lungs pleural effusion CRUK 0541 100x100 Novel treatment showing promise in patients with pleural mesotheliomaAdding a novel therapeutic option called Tumor Treating Fields to standard of care chemotherapy demonstrated clinically meaningful improvements in overall survival and progression-free survival in patients with pleural mesothelioma, according to top-line results from Novocure’s STELLAR phase 2 pilot trial.

Tumor Treating Fields, or TTFields, is a Food and Drug Administration (FDA)-approved treatment for some cancers, including some brain cancers, that slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The drug is not currently approved for patients. The study combined TTFields with standard of care chemotherapy, pemetrexed and cisplatin or carboplatin. Patients were compared to those who received standard of care chemotherapy alone.

The final data exceeded the results of the interim analysis for all efficacy endpoints that were presented December 2016 at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer. No device-related serious adverse events were reported. Full data is expected to be presented at an upcoming medical conference.

Based on the final results of STELLAR, Novocure plans to submit a Humanitarian Device Exemption (HDE) application to the FDA for approval in treating patients with pleural mesothelioma in the U.S.

Pleural mesothelioma is a rare but deadly type of lung cancer that develops gradually in the lining of the lungs. It is caused by exposure to , a mineral that was commonly used in the manufacture of cement, insulation and fireproof products. Mesothelioma may also affect the lining of the abdomen (peritoneal mesothelioma) or, rarely, the heart (pericardial mesothelioma).

Source: Street Insider

Comments are closed.